Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Cash (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Change in Cash for 6 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 122.13% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.2 million, a 160.57% decrease, with the full-year FY2024 number at $4.6 million, up 346.11% from a year prior.
  • Change in Cash was -$1.3 million for Q3 2025 at Vivos Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $20.1 million in Q2 2021 to a low of -$6.2 million in Q1 2022.
  • A 5-year average of -$795736.8 and a median of -$3.0 million in 2023 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 6463.13% in 2021; the steepest drop was 1043.96% in 2021.
  • Vivos Therapeutics' Change in Cash stood at -$4.5 million in 2021, then rose by 28.95% to -$3.2 million in 2022, then skyrocketed by 120.47% to $655000.0 in 2023, then plummeted by 107.79% to -$51000.0 in 2024, then crashed by 2478.43% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Change in Cash are -$1.3 million (Q3 2025), $2.1 million (Q2 2025), and -$3.9 million (Q1 2025).